BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Takeda Pharmaceuticals to Close Bay Area R&D Site; Unknown Number of Employees to be Eliminated


5/22/2012 7:40:47 AM

San Francisco Business Times by Ron Leuty, Reporter

Drug maker Takeda will close the South San Francisco site it once tagged as a key to developing early-stage antibody drugs.

The Japanese company said it is consolidating its South San Francisco and San Diego operations, now called Takeda California, in San Diego.

The move comes as Asia's largest drug maker deals with a falling stock price and declining sales of its best-selling drug, the diabetes treatment Actos, even as net income climbed, according to the news agency Bloomberg. It had announced the consolidation in December but held off until Friday on disclosing the fate of the Bay Area site.

Still, there were signs of a shift at the South San Francisco operation. Mary Haak-Frendscho, president of Takeda San Francisco since its formation in 2008, recently was named executive chairman of Compugen Ltd.'s newly formed South San Francisco-based U.S. subsidiary.

Takeda at one point employed 65 people in South San Francisco and expected to grow to as many as 100 employees. Takeda did not say how many people it currently employs locally, how many jobs will be eliminated, which jobs would shift to San Diego or how many people the southern California site ultimately will employ.

The company said in a press release late Friday that most "essential antibody and biologics research technologies and staff" will move to San Diego. The company added that the move was necessary "to enhance communication and collaboration, and to capture synergies by co-localizing its staff, management and research operations" into a single site.

The San Diego site will combine protein x-ray crystallography, small molecule, antibody and antibody-drug conjugate work targeting cancer, inflammatory diseases and metabolic diseases.

"This decision supports our continuous efforts to enhance the efficiency and effectiveness of Takeda's global research activities," Paul Chapman, senior vice president of Takeda's pharmaceutical research division, said in the release.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES